PL2740798T3 - Kompozycja leku do leczenia i/lub zapobiegania nowotworom - Google Patents
Kompozycja leku do leczenia i/lub zapobiegania nowotworomInfo
- Publication number
- PL2740798T3 PL2740798T3 PL12820775T PL12820775T PL2740798T3 PL 2740798 T3 PL2740798 T3 PL 2740798T3 PL 12820775 T PL12820775 T PL 12820775T PL 12820775 T PL12820775 T PL 12820775T PL 2740798 T3 PL2740798 T3 PL 2740798T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer treatment
- drug composition
- prevention drug
- prevention
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171303 | 2011-08-04 | ||
| EP12820775.0A EP2740798B1 (en) | 2011-08-04 | 2012-08-03 | Cancer treatment and/or prevention drug composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2740798T3 true PL2740798T3 (pl) | 2017-07-31 |
Family
ID=47629397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12820775T PL2740798T3 (pl) | 2011-08-04 | 2012-08-03 | Kompozycja leku do leczenia i/lub zapobiegania nowotworom |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9180188B2 (pl) |
| EP (1) | EP2740798B1 (pl) |
| JP (1) | JP6065592B2 (pl) |
| KR (1) | KR101968499B1 (pl) |
| CN (1) | CN103717737B (pl) |
| AU (1) | AU2012290946B2 (pl) |
| BR (1) | BR112014002614B1 (pl) |
| CA (1) | CA2844030C (pl) |
| DK (1) | DK2740798T3 (pl) |
| ES (1) | ES2618026T3 (pl) |
| HU (1) | HUE033183T2 (pl) |
| MX (1) | MX348581B (pl) |
| PL (1) | PL2740798T3 (pl) |
| PT (1) | PT2740798T (pl) |
| RU (1) | RU2595400C2 (pl) |
| WO (1) | WO2013018883A1 (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
| RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| JP5906739B2 (ja) * | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| HUE030130T2 (en) * | 2011-08-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| JP6094220B2 (ja) * | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| PL2818483T3 (pl) | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| AU2013241036B2 (en) | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| BR112015001100A2 (pt) | 2012-07-19 | 2018-03-27 | Toray Industries, Inc. | método de detecção de câncer |
| PT2876446T (pt) | 2012-07-19 | 2019-03-25 | Toray Industries | Método para deteção de cancro |
| TR201819812T4 (tr) | 2013-08-09 | 2019-01-21 | Toray Industries | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| JP7206590B2 (ja) | 2016-10-28 | 2023-01-18 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| SG11201907923VA (en) * | 2017-03-29 | 2019-09-27 | Agency Science Tech & Res | Anti oligosaccharide antibody |
| US20210121562A1 (en) | 2018-03-30 | 2021-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| MX2021015221A (es) | 2019-06-13 | 2022-03-17 | Bolt Biotherapeutics Inc | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. |
| US20220347310A1 (en) | 2019-09-30 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| JP2022553702A (ja) | 2019-10-25 | 2022-12-26 | ボルト バイオセラピューティクス、インコーポレーテッド | チエノアゼピン、イムノコンジュゲート、及びそれらの使用 |
| KR20220153615A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| JPWO2021182570A1 (pl) | 2020-03-12 | 2021-09-16 | ||
| WO2021182574A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| US20230293716A1 (en) | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| AU2021326516A1 (en) | 2020-08-13 | 2023-04-13 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| MX2023014498A (es) | 2021-06-23 | 2024-01-25 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| EP4360649A1 (en) | 2021-06-23 | 2024-05-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4378476A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023008461A1 (pl) | 2021-07-27 | 2023-02-02 | ||
| EP4378478A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20240051956A (ko) | 2021-09-03 | 2024-04-22 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| US20250000995A1 (en) | 2021-10-29 | 2025-01-02 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| JPWO2024005123A1 (pl) | 2022-06-30 | 2024-01-04 | ||
| AU2023329563A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023329558A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2024048542A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| ES2364266T3 (es) | 1998-04-03 | 2011-08-30 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado. |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1870466A3 (en) | 1998-07-14 | 2008-03-19 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| GB9815909D0 (en) * | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| EP1187915A2 (en) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| PL366626A1 (pl) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Kompozycje oraz sposoby leczenia i diagnozowania raka płuc |
| ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
| AU2002309063B8 (en) | 2001-05-11 | 2008-04-24 | Kyowa Kirin Co., Ltd. | Artificial human chromosome containing human antibody lambda light chain gene |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2179742A1 (en) | 2002-11-26 | 2010-04-28 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| NZ550225A (en) | 2004-03-30 | 2010-11-26 | Glaxo Group Ltd | Immunoglobulins that bind oncostatin and inhibit or block interaction between hOSM and pg130 |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| JP2008528486A (ja) | 2005-01-21 | 2008-07-31 | ジェネンテック・インコーポレーテッド | Ｈｅｒ抗体の一定投薬 |
| WO2006089212A2 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2007095186A2 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| US8454968B2 (en) | 2008-08-05 | 2013-06-04 | Toray Industries, Inc. | Method for inducing immunity with a peptide fragment from human CAPRIN-1 |
| JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
| RU2498819C2 (ru) * | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| CA2771441C (en) | 2009-08-19 | 2016-10-11 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| HUE030102T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer |
| CN102822199B (zh) | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| PT2532365T (pt) | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
| WO2011096535A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CN102821789B (zh) | 2010-02-04 | 2016-03-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| JP5906739B2 (ja) | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| US20110206976A1 (en) | 2010-02-19 | 2011-08-25 | Kyung-Mo Yoo | Electrode assembly and secondary battery using the same |
| JP2013012815A (ja) | 2011-06-28 | 2013-01-17 | Sony Corp | 画像処理装置及び画像処理方法 |
| CN103717740B (zh) | 2011-08-04 | 2015-10-21 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| AU2013241036B2 (en) | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
-
2012
- 2012-08-03 ES ES12820775.0T patent/ES2618026T3/es active Active
- 2012-08-03 PT PT128207750T patent/PT2740798T/pt unknown
- 2012-08-03 US US14/236,795 patent/US9180188B2/en active Active
- 2012-08-03 HU HUE12820775A patent/HUE033183T2/en unknown
- 2012-08-03 WO PCT/JP2012/069819 patent/WO2013018883A1/ja active Application Filing
- 2012-08-03 MX MX2014001374A patent/MX348581B/es active IP Right Grant
- 2012-08-03 AU AU2012290946A patent/AU2012290946B2/en active Active
- 2012-08-03 DK DK12820775.0T patent/DK2740798T3/en active
- 2012-08-03 CA CA2844030A patent/CA2844030C/en active Active
- 2012-08-03 KR KR1020147005862A patent/KR101968499B1/ko active Active
- 2012-08-03 RU RU2014108049/10A patent/RU2595400C2/ru active
- 2012-08-03 CN CN201280038464.0A patent/CN103717737B/zh active Active
- 2012-08-03 BR BR112014002614-9A patent/BR112014002614B1/pt active IP Right Grant
- 2012-08-03 JP JP2012543818A patent/JP6065592B2/ja active Active
- 2012-08-03 EP EP12820775.0A patent/EP2740798B1/en active Active
- 2012-08-03 PL PL12820775T patent/PL2740798T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX348581B (es) | 2017-06-20 |
| MX2014001374A (es) | 2014-03-21 |
| US20140193434A1 (en) | 2014-07-10 |
| CN103717737B (zh) | 2015-06-10 |
| CN103717737A (zh) | 2014-04-09 |
| WO2013018883A1 (ja) | 2013-02-07 |
| US9180188B2 (en) | 2015-11-10 |
| BR112014002614A2 (pt) | 2018-02-20 |
| RU2014108049A (ru) | 2015-09-10 |
| KR101968499B1 (ko) | 2019-04-12 |
| DK2740798T3 (en) | 2017-03-06 |
| EP2740798A4 (en) | 2015-04-15 |
| AU2012290946B2 (en) | 2016-04-21 |
| RU2595400C2 (ru) | 2016-08-27 |
| KR20140054182A (ko) | 2014-05-08 |
| BR112014002614B1 (pt) | 2022-09-20 |
| JPWO2013018883A1 (ja) | 2015-03-05 |
| PT2740798T (pt) | 2017-03-13 |
| CA2844030C (en) | 2019-09-03 |
| JP6065592B2 (ja) | 2017-01-25 |
| EP2740798A1 (en) | 2014-06-11 |
| AU2012290946A1 (en) | 2014-03-20 |
| ES2618026T3 (es) | 2017-06-20 |
| HUE033183T2 (en) | 2017-11-28 |
| EP2740798B1 (en) | 2016-12-07 |
| CA2844030A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
| HUE046788T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
| PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
| PT2832366T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar | |
| PL2832365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby | |
| PT2740489T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático | |
| PT2532367T (pt) | Agente farmacêutico para o tratamento e/ou prevenção do cancro | |
| IL225471B (en) | Preparations for the prevention and treatment of cancer | |
| PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| HUE039219T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| HUE042081T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| ZA201300692B (en) | Administration of hypoxia activated prodrugs and antiagiogenic agents for the treatment of cancer | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| HK1201730A1 (en) | Treatment agent and or prophylactic agent for side effects of cancer drugs | |
| ES3009438T3 (en) | Method and pharmaceutical composition for use in the treatment of cancer | |
| HK1211221A1 (en) | Formulations for the treatment and prevention of obesity | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer |